Mkts

Halozyme Therapeutics, Inc.

NASDAQ: HALO
$93.04-2.76 (-2.88%)
As of Nov 19, 4:00 PM ET

Key statistics

Day range
91.1994.57
52-week range
61.23134.00
Today
Open92.74
Previous close93.04
Volume92.9K
Valuation
Market cap10.92B
P/E ratio26.41×
EPS (TTM)3.35
Income & risk
Dividend / yield—
Beta0.96
Avg volume2.23M
Discussion

HALO News

Stories mentioning HALO from around the web — every one is an open thread, so give it a like or add your take.

All news →

Loading news…

Financial statements

Financial statements

As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.

Line itemQ1 '26Mar 31Q4 '25Dec 31Q3 '25Sep 30Q2 '25Jun 30Q1 '25Mar 31Q4 '24Dec 31Q3 '24Sep 30Q2 '24Jun 30
Income Statement
Revenue376,708451,767354,264325,719264,861298,008290,084231,353
Cost of Goods Sold79,23878,77055,24246,35948,40342,05549,42639,607
Gross Profit297,470372,997299,022279,360216,458255,953240,658191,746
Operating Expenses
Research & Development25,56017,25117,54314,79920,44118,45821,038
Sales General & Admin57,88177,02846,08841,61442,36242,24941,24135,711
Total Operating Expenses
Operating Income (Loss)184,517(92,891)217,921202,441141,535175,501163,197117,235
Interest Income
Interest Expense
Other Expense1,3182,4305,3336,8916,8187,2536,4745,032
Pretax Income180,327(100,849)218,958204,938143,828178,214165,147117,743
Tax Provision30,27840,74243,73339,77825,73341,20228,13624,498
Net Income (Loss)150,049(141,591)175,225165,160118,095137,012137,01193,245
Earnings Per Share (Basic)1.27(1.18)1.491.360.961.081.080.73
Earnings Per Share (Diluted)1.22(1.14)1.431.330.931.061.050.72
Weighted Average Shares Outstanding (Basic)118,144119,840117,219121,343123,215126,827126,850127,116
Weighted Average Shares Outstanding (Diluted)122,875123,904122,331124,158126,644129,424130,134129,222

Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.

Key facts

About HALO

Halozyme Therapeutics, Inc. (NASDAQ: HALO) is a stock listed on the Nasdaq Stock Market under the ticker symbol HALO. It last traded at $93.04 (Nov 19, 2026, 4:00 PM ET), down 2.9% on the day. That gives Halozyme Therapeutics a market capitalisation of $10.9B and a price-to-earnings ratio of 26.4.

Over the past 52 weeks HALO has traded between $61.23 and $134.00.

Revenue for the quarter ended Mar 31, 2026 was $376.7M; net income $150.0M. Revenue was up 42.2% from $264.9M in the quarter ended Mar 31, 2025.

Last 4 quarters
Quarter endedRevenueNet incomeMargin
Mar 31, 2026$376.7M$150.0M39.8%
Dec 31, 2025$451.8M-$141.6M-31.3%
Sep 30, 2025$354.3M$175.2M49.5%
Jun 30, 2025$325.7M$165.2M50.7%

From Halozyme Therapeutics’s quarterly (10-Q) filings, in US dollars.

Latest News

Market news from around the web — every story is an open thread, so give it a like or add your take.

All news →

Loading news…